Preview

Медицинский Совет

Расширенный поиск

Вторая линия терапии гастроинтестинальных стромальных опухолей: ожидает ли нас выбор?

https://doi.org/10.21518/2079-701X-2019-10-28-36

Полный текст:

Аннотация

Гастроинтестинальные стромальные опухоли (ГИСО) являются редкими мезенхимальными новообразованиями. В настоящее время возможно проведение трех последовательных линий таргетной терапии диссеминированных ГИСО: первая линия – иматиниб, вторая линия – сунитиниб, третья линия – регорафениб. Статус мутации гена c-KIT является предиктором чувствительности ГИСО к иматинибу и сунитинибу. Часть больных прерывают лечение сунитинибом из-за выраженной токсичности. Регорафениб может быть использован во второй линии терапии ГИСО при непереносимости сунитиниба.

Об авторах

А. М. Королева
Многопрофильная клиника «Реавиз».
Россия

врач-онколог многопрофильной клиники «Реавиз».



Л. М. Когония
Государственное бюджетное учреждение здравоохранения Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского».
Россия

д.м.н., профессор кафедры онкологии и торакальной хирургии факультета усовершенствования врачей Государственного бюджетного учреждения здравоохранения Московской области «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского».



Список литературы

1. Sakurai S., Fukasawa T., Chong J. et al. C-kit gene abnormalities in gastrointestinal stromal tumors. Jpn. J. Cancer Res. 1999;90:1321-1328.

2. Mazur M., Clark H. Gastric stromal tumors: R=re appraisal of histogenesis. Am. J. Surg. Pathol. 1983;7:507-519.

3. Sarlomo-Rikala M., Kovatich A., Barusevicius A. et al. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathology. 1998;11:728-734.

4. Demetri G., Benjamin R., Blanke C. et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl. Compr. Canc. Netw. 2007;5(Suppl. 2):S1-S29.

5. Kindblom L.G., Remotti H.E., Aldenborg F. et al. Gastrointestinal pacemaker cell tumor: Gasrtrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathology. 1998;152:1259-1269.

6. Hirota S., Isozaki K., Moriyama Y. et al. Gainfunction mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.

7. Arber D.A., Tamayo R., Weiss L.M. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathology. 1998;28:498-504.

8. West R.B. et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am. J. Pathol. 2004;165:07-113.

9. Polkowski M., Butruk E. Submucosal lesions. Gastrointest. Endosc. Clin. N. Am. 2005;15:33–54.

10. Miettinen M., Sobin L., Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochmical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol. 2005;29:52-68.

11. Miettinen M., Makhlouf H., Sobin L. et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochmical, and molecular genetic study of 906 cases before imatinib with long-term followup. Am. J. Surg. Pathol. 2006;30:477-89.

12. Singer S., Rubin B., Fletcher A. et al. Prognostic value of kit mutation type, mitotic activity, and histological subtype in gastrointestinal stromal tumors. J. of Clin. Oncol. 2002;20(18):3898-3905.

13. Fletcher C., Berman J., Corless C. et al. Diagno sis of gastrointestinal stromal tumors: a consensus approach. Human Pathology. 2002;33(5):459-465.

14. Цыганова И.В., Анурова О.А., Мазуренко Н.Н. Морфологические особенности и критерии прогноза стромальных опухолей желудочно- кишечного тракта. Архив патологии. 2011;73(6):37–42. [Tsyganova I.V., Anurova O.A., Mazurenko N.N. Morphological features and criteria of stromal tumors prognosis of gastrointestinal tract. Arhiv patologii. 2011;73(6):37–42.] (In Russ.)

15. Joensuu H., Rutkowski P., Nishida T. et al. KIT and PDGFRA mutations and the riskof GI stromal tumor recurrence. J. Clin. Oncol. 2015;33(6):634–42.

16. Corless C.L., Heinrich M.C. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol. 2008;3:557–86.

17. Andersson J., Bümming P., Meis-Kindblom J.M. et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130(6):1573–1581.

18. Liu X.H., Bai C.G., Xie Q. et al. Prognostic value of KIT mutation in gastrointestinal stromal tumors. World J. Gastroenterol. 2005;11(25):3948–3952.

19. Antonescu C.R., Viale A., Sarran L. et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin. Cancer Res. 2004;10(10):3282–3290.

20. Blay J.Y. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 2011;37:373-384.

21. Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus vs infusion in patients with soft tissue sarcomas. SWOG study. Jour. Nath. Cancer Inst. 1991;83:926-932.

22. Edmonson J., Maarks R., Buckner J. et al. Contrast of response to D-MAP plus sargramostin between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc. Am. Assoc. Cancer Res. 1999;18:abst 541.

23. Antman K., Crowley J., Balcerzak S. et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993;11:1276-1285.

24. van Oosterom A.T., Judson I.R., Verweij J. et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 2002;38(Suppl. 5):83-87.

25. Van den Abbelle A.D.18-FDG-PET provides early evidence of biological response to STI- 571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc. Am. Soc. Clin. Oncol. 2001;20:362.

26. Verweij J., Casali P., Zalcberg J., Cesne A. et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors: interim results of a randomized phase III trial from the EORTCSTBSG, ISG and AGITG. Proc. Am. Soc. Clin. Oncol. 2003;22:3272a.

27. Benjamin R., Rankin C., Fletcher C. et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results. Proc. Am. Soc. Clin. Oncol. 2003;22:3271a.

28. Boikos S.A., Pappo A.S., Killian J.K. et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922–928.

29. Никулин М.П., Архири П.П., Владимирова Л.Ю. и соавт. Практические рекомендации по лекарственному лечению гастроинтестинальных стромальных опухолей. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018;8:421-429. [Nikulin M.P., Archiri P.P., Vladimirova L.Yu. et al. Practical recommendations for the treatment of gastrointestinal stromal tumors. Zlokachestvennye opuholi: Prakticheskie rekomendacii RUSSCO #3s2. 2018;8:421-429.] (In Russ.)

30. Корнилова А.Г., Когония Л.М., Моськин В.Г. и соавт. Гастроинтестинальные стромальные опухоли: современная классификация, дифференциальная диагностика и факторы прогноза. Эффективная фармакотерапия. 2014;3(47):12-16. [Kornilova A.G., Kogonia L.M., Moskin V.G. et al. Gastrointestinal stromal tumors: modern classification, differential diagnostics and prognosis factors. Effektivnaya farmakoterapiya. 2014;3(47):12-16.] (In Russ.)

31. Zalcberg J.R., Verweij J., Casali P.G. et al. Outcome of patients with advanced gastrointestinal stro-mal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41(12):1751–1757.

32. De Matteo R., Ballman k., Antonescu C. et al. Adjuvant imatinib mesylate after resection of localized primary gastrointestinal stromal tumor: a randomized, double-blind, placebo controlled trial. Lancet. 2009;373(9669):1097-1104.

33. Корнилова А.Г., Когония Л.М., Мазурин В.С. и соавт. Гастроинтестинальные стромальные опухоли: что нового в терапии? Сибирский онкологический журнал. 2015;2:81-87. [Kornilova A.G., Kogonia L.M., Mazurin V.S. et al. Gastrointestinal stromal tumors: what is new in therapy? Sibirskij onkologicheskij zhurnal. 2015;2:81-87] (In Russ.)

34. Адлейба С.Т., Когония Л.М., Мазурин В.С. Оптимизация методики лекарственной терапии больных с гастроинтестинальными стромальными опухолями. Российский биотерапевтический журнал. 2018;17:2-3. [Adleiba S.T., Kogonia L.M., Mazurin V.S. Optimization of the method of drug therapy for patients with gastrointestinal stromal tumors. Rossijskij bioterapevticheskij zhurnal. 2018;17:2-3.] (In Russ.)

35. ESMO Update Clinical Practice Guidelines. Ann. of Oncol. 2012;23(Suppl. 7).

36. Heinrich M.C., Corless C.L., Demetri G.D. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003;21(23):4342–4349.

37. Demetri G.D., et al. SU 11248, a multitargeted tyrosine kinase inhibitor, can overcome imatinib – resistance caused by diverse genomic mechanisms in patients with metastatic gastrointestinal stromal tumor. Proceedings ASCO. 2004:abstr. 3001.

38. Liegl B., Kepten I., Le C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 2008;216(1):64–74.

39. Van Glabbeke M., Verweij J., Casali P.G., et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group- Australasian Gastrointestinal Trials Group. J Clin Oncol. 2005;23(24):5795–5804.

40. Heinrich M.C., Maki R.G., Corless C.L. et al. Sunitinib (SU) response in imatinib-resistance (IM-R) GIST correlates with KIT and PDGFRA mutation status. J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(18S. Suppl.):Abstract. 9502.

41. Heinrich M.C., Maki R.G., Corless C.L. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol. 2008;26(33):5352–5359.

42. George S., Blay J.I., Casali P.G. et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer. 2009;45:1959-68.

43. Morgan J. et al. Patients with Imatinibmesylate- resistant GIST exhibit durable responses to Sunitinib alate (SU11248).17th ICACT, 2008, poster session.

44. Demetri G.D., Heinrich M.C., Fletcher J.A. et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15(18):5902–5909.

45. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic metaanalysis. Cancer Chemother Pharmacol. 2010;66(2):357–371.

46. Demetri G.D., van Oosterom A.T., Garrett C.R. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338.

47. Demetri G.D., Huang X., Garrett C.R. et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. 2008;26(15S):559s.

48. Reichardt P., Kang Y., Ruka W. et al. Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol. 2008;26(15S):565s.

49. Duffaud F., Ray-Coquard I., Marchal F. et al. Clinical experience with sunitinib (SU) in patients over age 65 with metastatic gastrointestinal stromal tumors (GIST): a retrospective study from the French Sarcoma Group (FSG). J Clin Oncol. 2013;31(suppl):abstr 10546.

50. Chen Y.-Y., Yeh C.-N., Cheng C.-T. et al. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol. 2011;17(16):2113–2119.

51. Li J., Gao J., Hong J., Shen L. Efficacy and safety of sunitinib in Chinese patients with imatinibresistant or -intolerant gastrointestinal stromal tumors. Future Oncol. 2012;8(5):617–624.

52. Shen L., Qin S., Sun Y. et al. Sunitinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST). J Clin Oncol. 2015;33(suppl) abstr e15208.

53. George S., Reichardt P., Lechner T., Li S., Cohen D.P., Demetri G.D. Hypertension as a potential bi-omarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180–3187.

54. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–2019.

55. Di Lorenzo G., Autorino R., Bruni G. et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20(9):1535–1542.

56. Wolter P., Stefan C., Decallonne B. et al. The clinical implications of sunitinib-induced hypothy-roidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–454.

57. Tielen R., Verhoef C., van Coevorden F. et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol. 2012;10:111.

58. Raut C.P., Wang Q., Manola J. et al. Cytoreductive surgery in patients with metastatic gastroin-testinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010;17(2):407–415.

59. Vincenzi B., Nannini M., Fumagalli E. et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget. 2016 Oct 25;7(43):69412–69419.

60. Hislop J., Mowatt G., Sharma P. et al. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastroin-testinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer. 2012;43(2):168–176.

61. Guo T., Hajdu M., Agaram N.P. et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res. 2009;15(22):6862–6870.

62. Rutkowski P., Bylina E., Klimczak A. et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure – one institution study. BMC Cancer. 2012;12:107.

63. George S., Reichardt P., Lechner T., Li S., Cohen D.P., Demetri G.D. Hypertension as a potential bi-omarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180–3187.

64. Liegl B., Kepten I., Le C. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216(1):64–74.

65. Deprimo S.E., Huang X., Blackstein M.E. et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009;15(18):5869–5877.

66. Hansson E.K., Amantea M.A., Westwood P. et al. PKPD modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. CPT Pharmacometrics Syst Pharmacol. 2013;2:e84.

67. Mross K., Frost A., Steinbild S. et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 2012;18:2658–67.

68. George S., Wang Q., Heinrich M.C. et al. Efficacy and safety of regorafenib in patients with metastatic and/or uresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J. Clin. Oncol. 2012;30:2401–07.

69. George S., Feng Y., von Mehren M. et al. Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: response based on genotype. ASCO Meet. Abstr. 2013;31:10511.

70. Demetri G.D., Reichardt P., Kang Y.K. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet. 2013;381:295-302.

71. Demetri G., Reichardt P., Kang Y.-K. et al. Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stro-mal tumors (GIST). Journal of Clinical Oncology. 2016 February;134(4_suppl):156-156.

72. Starczewska A., Rusafa J.C., Desai K. et al. Prevalence of gastrointestinal stromal tumours (GIST) in the United Kingdom in different therapeutic lines: an epidemiologic model. BMC Cancer. 2014;14:364.

73. Yeh C.N., Chen T.W., Tseng J.H., Liu Y.Y., Wang S.Y., Tsai C.Y., Chiang K.C., Hwang T.L., Jan Y.Y., Chen M.F. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010;102:599–603.

74. Gao J., Tian Y., Li J., Sun N., Yuan J., Shen L. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors. Med Oncol. 2013;30:522.

75. Yeh C.N., Chen M.H., Chen Y.Y. et al. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget. 2017 Jul 4;8(27):44121-44130.

76. Reichardt P., Kang Y.-K., Rutkowski P. Clinical Outcomes of Patients with Advanced Gastrointestinal.Stromal Tumors: Safety and Efficacy in a Worldwide Treatment-use Trial of Sunitinib. Cancer. 2015 May 1;121(9):1405–1413.

77. Shah R.R., Morganroth J., Shah D.R. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503.

78. Chu D., Lacoutore M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin. Genitourin. Cancer. 2009;7(1):11-19.

79. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9-17.

80. Chu T.F., Rupnick M.A., Kerkela R. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9.

81. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009;6:465-477.

82. Jones R.L., Bendell J.C., Smith D.C. et al. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 2015;76(4):777–784.


Для цитирования:


Королева А.М., Когония Л.М. Вторая линия терапии гастроинтестинальных стромальных опухолей: ожидает ли нас выбор? Медицинский Совет. 2019;(10):28-36. https://doi.org/10.21518/2079-701X-2019-10-28-36

For citation:


Kogonia L.M., Koroleva A.M. Second line of therapy for gastrointestinal stromal tumors: is there a choice? Medical Council. 2019;(10):28-36. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-28-36

Просмотров: 54


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)